查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1458429

印度医用大麻市场评估：依物种、衍生物、给药途径、形式、治疗用途、最终用户和地区划分的机会和预测（2017 财年-2031 财年）

India Medical Cannabis Market Assessment, By Species, By Derivatives, By Route of Administration, By Form, By Therapeutic Application, By End-user, By Region, Opportunities and Forecast, FY2017-FY2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 128 Pages | 商品交期: 3-5个工作天内

价格

印度医用大麻市场规模预计将从 2023 年的 1,536 万美元成长到 2031 年的 4,715 万美元，2024-2031 年的复合年增长率为 15.05%。

印度医用大麻市场的成长是由焦虑和忧郁症的盛行率不断上升、医疗产业中医用大麻的使用不断增加以及领先公司研究医用大麻在各种医疗条件下的潜在益处所推动的。，包括公司研发活动的增加。此外，人们对安全使用医用大麻治疗癫痫和疼痛等健康状况的接受度不断提高，也促进了印度市场的成长。

印度医用大麻市场由于其治疗焦虑、忧郁、慢性疼痛和癫痫的潜力而正在经历显着增长。医用大麻衍生物，如大麻二酚，以多种形式出售，包括 CBD 油、胶囊和外用乳膏，可以缓解疼痛和具有治疗作用。因此，一些公共机构和私人公司越来越多地投资于研发活动，以加强这些产品在治疗其他疾病方面的用途。这些因素正在推动印度医用大麻市场的成长。

有利的监管框架、新的市场进入、併购、伙伴关係、公司间分销协议等合作活动的增加以及主要参与者持续推出的创新产品也将进一步推动印度医用大麻市场的发展。2023 年 2 月，总部位于孟买的工业大麻和医用大麻公司 Bombay Hemp Company (BOHECO) 推出了多项医疗创新产品，包括缓解关节疼痛的 GLIDE+ 和改善湿疹的 PRISTINE 等。我们也透过将这些产品出口到海外来扩大我们的销售管道。如此频繁的产品推出预计也将推动印度医用大麻市场的发展。

忧郁症患者增加：

由于印度焦虑和忧郁等心理健康问题日益普遍，对医用大麻的需求大幅增加。心理健康障碍变得越来越普遍，影响着不同年龄层和地区的大量个体。根据Sapien Labs Centre for the Human Brain and Mind at Krea University编製并发布的《Mental State of India Rapid Report 2023》，2020年，有网路存取的印度人口中，有46%面临心理健康问题，这一比例还将继续上升到 2023 年将达到 50%。这说明印度人的心理健康状况正在逐年恶化。失业、过度使用智慧型手机和不健康的生活方式是导致人们心理健康状况不佳的主要原因。医用大麻产品可能被证明是解决这一日益严重的心理健康状况不佳问题的有效解决方案。

该报告调查了印度的医用大麻市场，并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构、影响市场增长的因素分析以及案例研究。简介等

目录

第一章研究方法论

第二章 专案范围与定义

第 3 章执行摘要

第四章 印度医用大麻市场展望

  • 市场规模/预测
  • 类型
    • 籼稻
    • 苜蓿
    • 杂交种
  • 依衍生产品分类
    • 大麻二酚 (CBD)
    • 四氢大麻酚 (THC)
    • 其他
  • 依给药途径
    • 口服
    • 当地的
    • 其他
  • 依形式
    • Oil
    • 胶囊
    • 酊剂
  • 依治疗用途
    • 癌症
    • 偏头痛
    • 癫痫
    • 焦虑/忧郁
    • 其他
  • 依最终用户
    • 製药业
    • 研发中心
    • 其他
  • 依地区
    • 北方
    • 南部
    • 东
    • 西部/中部地区
  • 市占率：依公司划分，2023 财年

第 5 章 市场测绘，2023 年

  • 类型
  • 依衍生产品分类
  • 依给药途径
  • 依形式
  • 依治疗用途
  • 依最终用户
  • 依地区

第六章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第七章市场动态

  • 生长促进因子
  • 生长抑制因素（问题/限制）

第八章 监理框架与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新兴技术

第九节 主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析
  • 併购/合资（如适用）
  • SWOT分析（5家参与企业）
  • 专利分析（如果适用）

第10章价格分析

第11章案例研究

第十二章 主要公司展望

  • Hemp Organics Pvt Ltd (India Hemp Organics)
  • Ananta Hempworks Solutions Pvt. Ltd.
  • Bombay Hemp Company Private Limited (BOHECO)
  • HempCann Solutions Pvt. Ltd. (Vedi)
  • Indian Industrial Hemp Association
  • Hemp Horizons Private Limited
  • VeganMall
  • CannazoIndia
  • Cannarie (Varka Labs Private Limited)
  • Cannarma Private Limited

第十三章 战略建议

第14章关于我们公司/免责声明

Product Code: MX10029

India medical cannabis market is projected to witness a CAGR of 15.05% during the forecast period FY2024-FY2031, growing from USD 15.36 million in FY2023 to USD 47.15 million in FY2031. India medical cannabis market growth is driven by various factors, such as increasing prevalence of anxiety and depression, increased applications of medical cannabis in the healthcare industry, and increase in research and development (R&D) activities by leading players to study the potential benefits of medical cannabis in different medical conditions. Growing acceptance among the people regarding the safe usage of medical cannabis for health conditions, such as epilepsy and pain management, is also leading to the growth of this market in India.

The India medical cannabis market is undergoing significant growth due to its potential in treating anxiety, depression, chronic pain, and epilepsy. Medical cannabis derivatives, such as cannabidiol, is available in various forms, including CBD oils, capsules, and topical creams, that provide pain relief and therapeutical advantages. Due to which, several public and private organizations are increasingly investing in R&D activities to enhance use of these products to treat other medical conditions. These factors are driving the growth of the India medical cannabis market.

Favorable regulatory framework, new entrances in the market, increased collaboration activities, such as mergers and acquisitions, partnerships, and distribution agreements between the companies, along with consistent innovative product launches by key market players, further propels the India medical cannabis market. For Instance, in February 2023, Bombay Hemp Company (BOHECO), which is a Mumbai-based industrial hemp and medical cannabis company, launched several innovative medical cannabis-based products such as GLIDE+ for joint pain relief and PRISTINE for improvement in eczema. Along with this, the company is also expanding its market reach by exporting these products to several international destinations. These frequent product launches are expected to flourish the India medical cannabis market.

Increasing Prevalence of Depression

The demand for medical cannabis has significantly increased due to the growing prevalence of mental health issues like anxiety and depression among the Indian population. Mental health conditions are becoming increasingly common, affecting a substantial number of individuals across various age groups and geographical locations. For instance, according to Mental State of India Rapid Report 2023, conducted and published by the "Sapien Labs Centre for the Human Brain and Mind at Krea University", 46% of the internet-enabled Indian population were dealing with poor mental health in the year 2020 and this percentage has increased to 50% in the year 2023. This indicates that the mental health of the Indian population is gradually affecting over the years. Unemployment, excessive use of smart-phones, and unhealthy lifestyles are the main drivers for this increasing poor mental health of the population. Medical cannabis-based products can prove to be an effective solution for this growing poor mental health issue. Numerous research studies have demonstrated medical cannabis effectiveness in treating depression and anxiety, resulting in significant enhancements in people's health conditions. As a result, many companies are integrating medical cannabis in their product portfolio for a variety of health conditions, such as pain, migraines, cancer, and epilepsy, thereby driving the growth of the Indian medical cannabis market.

Favorable Regulatory Framework

India medical cannabis market size is influenced by the implementation of favorably regulatory framework by the Government of India (GoI). These considerations within the regulatory bodies to approve novel medical cannabis-based products in the healthcare sector can be attributed to the growing demand for medical cannabis, increasing R&D activities, and growing awareness regarding the tremendous potential of medical cannabis in treating several health conditions. For instance, in May 2023, Biophore India Pharmaceuticals announced that its subsidiary, "Zenara Pharma" has received approval from the Central Drugs Standard Control Organization to manufacture medical cannabis-based products in India. This approval has been granted for treating seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. These favorable regulatory policies are expected to accelerate the growth of the India medical cannabis market.

Increased Demand for Cannabidiol

Among the derivative segment, cannabidiol (CBD) segment holds significant market share in the India medical cannabis market. In comparison with THC, CBD-based products are used in vast medical applications such as pain management, epilepsy, and cancer. CBD-based products are legalized and are easy to access, which makes them highly popular among the manufacturers and consumers. Additionally, several leading players are launching CBD-based products in their portfolio for various medical purposes, which is boosting the India medical cannabis market demand. For instance, in April 2023, Cansaa, which is Chennai's first medical cannabis clinic, has been opened to provide treatment by using combination of ayurveda and functional medicines such as CBD oils, tinctures, creams, and acupuncture. As the awareness regarding the potential benefits of CBD in healthcare industry is increasing, more healthcare settings are expected to adopt CBD-based products in their services. These factors are escalating growth in the India medical cannabis market.

Increased Demand of Medical Cannabis in Epilepsy

Among the therapeutic application segment, medical cannabis is widely used for the treatment of epilepsy and thus, this segment holds a significant market share in the overall India medical cannabis market. Several studies have shown that medical cannabis exuberates promising effects in the treatment of epilepsy, especially in certain epileptic conditions. For instance, an article published in the "Behavioral Neurology Journal" in the year 2023, states that medical cannabis has potential therapeutic applications in treating neurological conditions such as epilepsy, multiple sclerosis, Alzheimer's, and Parkinson's disease. Due to this, regulatory bodies, such as the European Medicines Agency and the U.S. Food and Drug Administration, have approved medical cannabis-based products, such as CBD oil, for use in certain epilepsy treatments. Moreover, frequent innovative and advanced product launches by key market players in this industry, to provide quality treatment, further accelerates growth of this segment in India.

Future Market Scenario (FY2024 - FY2031F)

The India medical cannabis market is expected to grow in the future, due to multiple factors. Primarily, the increasing prevalence of anxiety and depression among the population has enhanced company's focus in developing medical cannabis-based products that can help with relieving mental stress among the users. Increased acceptance among the healthcare providers regarding the capabilities of medical cannabis in the treatment of anxiety, depression, epilepsy has enabled the pharmaceutical companies to increase investments in this market. There has been a surge in research and development activities in this market to further explore the potential benefits of medical cannabis in patient's treatments. Collaborative ventures among the companies, improved and supportive regulatory framework and new entrances have spurred growth in the India medical cannabis market. For Instance, Cannarma, which is a growing start-up established in the year 2022, that manufactures a wide range of ayurvedic products, such as CBD oil, hemp seed oil, and medicinal cannabis announced its plan to establish around 10,000 medical stores, clinics, and hospitals throughout India, expanding its domestic market. These potential new entrants are further leading to the growth in the India medical cannabis market.

Key Players Landscape and Outlook

Numerous pharmaceutical companies are consistently forming strategic partnerships and distribution agreements, which plays a crucial role in driving the expansion of the Indian medical cannabis market. These partnerships allow firms to gain valuable insights into the market, leverage each other's resources, markets, and technologies, and invest in research and development activities to bring advancements to the market. Distribution agreements enable companies to expand their market presence at a national level in India. These collaborative initiatives foster innovation, expertise in product development, and contribute to the sustained and robust growth of the Indian market. For instance, in July 2023, Carer, which is a Bengaluru-based startup, announced its collaboration partnership with Wholeleaf, which is a licensed medical cannabis company. This strategic collaboration aims to improve the quality of life of cancer patients by providing medical cannabis-based products that can ease pain and improve physical and mental well-being of the patients. These consistent collaboration activities further assist in the India medical cannabis market expansion.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.India Medical Cannabis Market Outlook, FY2017-FY2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Species
    • 4.2.1.Indica
    • 4.2.2.Sativa
    • 4.2.3.Hybrid
  • 4.3.By Derivatives
    • 4.3.1.Cannabidiol (CBD)
    • 4.3.2.Tetrahydrocannabinol (THC)
    • 4.3.3.Others
  • 4.4.By Route of Administration
    • 4.4.1.Oral
    • 4.4.2.Topical
    • 4.4.3.Others
  • 4.5.By Form
    • 4.5.1.Oils
    • 4.5.2.Capsules
    • 4.5.3.Tinctures
  • 4.6.By Therapeutic Application
    • 4.6.1.Cancer
    • 4.6.2.Migraine
    • 4.6.3.Epilepsy
    • 4.6.4.Anxiety and Depression
    • 4.6.5.Others
  • 4.7.By End-user
    • 4.7.1.Pharmaceutical Industry
    • 4.7.2.Research and Development Centers
    • 4.7.3.Others
  • 4.8.By Region
    • 4.8.1.North
    • 4.8.2.South
    • 4.8.3.East
    • 4.8.4.West and Central
  • 4.9.By Company Market Share (%), FY2023

5.Market Mapping, FY2023

  • 5.1.By Species
  • 5.2.By Derivatives
  • 5.3.By Route of Administration
  • 5.4.By Form
  • 5.5.By Therapeutic Application
  • 5.6.By End-user
  • 5.7.By Region

6.Macro Environment and Industry Structure

  • 6.1.Demand Supply Analysis
  • 6.2.Import Export Analysis
  • 6.3.Value Chain Analysis
  • 6.4.PESTEL Analysis
    • 6.4.1.Political Factors
    • 6.4.2.Economic System
    • 6.4.3.Social Implications
    • 6.4.4.Technological Advancements
    • 6.4.5.Environmental Impacts
    • 6.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 6.5.Porter's Five Forces Analysis
    • 6.5.1.Supplier Power
    • 6.5.2.Buyer Power
    • 6.5.3.Substitution Threat
    • 6.5.4.Threat from New Entrant
    • 6.5.5.Competitive Rivalry

7.Market Dynamics

  • 7.1.Growth Drivers
  • 7.2.Growth Inhibitors (Challenges and Restraints)

8.Regulatory Framework and Innovation

  • 8.1.Clinical Trials
  • 8.2.Patent Landscape
  • 8.3.Regulatory Approvals
  • 8.4.Innovations/Emerging Technologies

9.Key Players Landscape

  • 9.1.Competition Matrix of Top Five Market Leaders
  • 9.2.Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
  • 9.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 9.4.SWOT Analysis (For Five Market Players)
  • 9.5.Patent Analysis (If Applicable)

10.Pricing Analysis

11.Case Studies

12.Key Players Outlook

  • 12.1.Hemp Organics Pvt Ltd (India Hemp Organics)
    • 12.1.1.Company Details
    • 12.1.2.Key Management Personnel
    • 12.1.3.Products & Services
    • 12.1.4.Financials (As reported)
    • 12.1.5.Key Market Focus & Geographical Presence
    • 12.1.6.Recent Developments
  • 12.2.Ananta Hempworks Solutions Pvt. Ltd.
  • 12.3.Bombay Hemp Company Private Limited (BOHECO)
  • 12.4.HempCann Solutions Pvt. Ltd. (Vedi)
  • 12.5.Indian Industrial Hemp Association
  • 12.6.Hemp Horizons Private Limited
  • 12.7.VeganMall
  • 12.8.CannazoIndia
  • 12.9.Cannarie (Varka Labs Private Limited)
  • 12.10. Cannarma Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13.Strategic Recommendations

14.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.India Medical Cannabis Market, By Value, In USD Million, FY2017-FY2031F
  • Figure 2.India Medical Cannabis Market, By Volume, In Million Units, FY2017-FY2031F
  • Figure 3.India Medical Cannabis Market Share (%), By Species, FY2017-FY2031F
  • Figure 4.India Medical Cannabis Market Share (%), By Derivatives, FY2017-FY2031F
  • Figure 5.India Medical Cannabis Market Share (%), By Route of Administration, FY2017-FY2031F
  • Figure 6.India Medical Cannabis Market Share (%), By Form, FY2017-FY2031F
  • Figure 7.India Medical Cannabis Market Share (%), By Therapeutical Application, FY2017-FY2031F
  • Figure 8.India Medical Cannabis Market Share (%), By End-user, FY2017-FY2031F
  • Figure 9.India Medical Cannabis Market Share (%), By Region, FY2017-FY2031F
  • Figure 10.By Species Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 11.By Derivatives Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 12.By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 13.By Form Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 14.By Therapeutical Application Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 15.By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2023
  • Figure 16.By Region Map-Market Size (USD Million) & Growth Rate (%), FY2023